UNLABELLED: Growth hormone (GH) treatment in young adults with childhood-onset GH deficiency has beneficial effects on bone mass. The present study shows that cortical bone dimensions also benefit from GH treatment, with endosteal expansion and increased cortical thickness leading to improved bone strength. INTRODUCTION: In young adults with childhood-onset growth hormone deficiency (CO GHD), GH treatment after final height is reached has been shown to have beneficial effects on spine and hip bone mineral density. The objective of the study was to evaluate the influence of GH on cortical bone dimensions. METHODS:Patients (n = 160; mean age, 21.2 years; 63% males) with CO GHD were randomised 2:1 to GH or no treatment for 24 months. Cortical bone dimensions were evaluated by digital x-ray radiogrammetry of the metacarpal bones every 6 months. RESULTS: After 24 months, cortical thickness was increased compared with the controls (6.43%, CI 3.34 to 9.61%; p = 0.0001) and metacarpal index (MCI) (6.14%, CI 3.95 to 8.38%; p < 0.0001), while the endosteal diameter decreased (-4.64%, CI -7.15 to -2.05; p < 0.001). Total bone width did not change significantly (0.68%, CI -1.17 to 2.57%; not significant (NS)). A gender effect was seen on bone width (p < 0.0001), endosteal diameter (p < 0.01) and cortical thickness (p < 0.01), but not with MCI (NS). CONCLUSIONS: Cortical bone reacts promptly to reinstitution of GH beyond the attainment of final height by increasing the cortical thickness through endosteal bone growth. This leads to a higher peak bone mass and may reduce the risk of cortical bone fragility later in life.
RCT Entities:
UNLABELLED: Growth hormone (GH) treatment in young adults with childhood-onset GH deficiency has beneficial effects on bone mass. The present study shows that cortical bone dimensions also benefit from GH treatment, with endosteal expansion and increased cortical thickness leading to improved bone strength. INTRODUCTION: In young adults with childhood-onset growth hormone deficiency (CO GHD), GH treatment after final height is reached has been shown to have beneficial effects on spine and hip bone mineral density. The objective of the study was to evaluate the influence of GH on cortical bone dimensions. METHODS:Patients (n = 160; mean age, 21.2 years; 63% males) with CO GHD were randomised 2:1 to GH or no treatment for 24 months. Cortical bone dimensions were evaluated by digital x-ray radiogrammetry of the metacarpal bones every 6 months. RESULTS: After 24 months, cortical thickness was increased compared with the controls (6.43%, CI 3.34 to 9.61%; p = 0.0001) and metacarpal index (MCI) (6.14%, CI 3.95 to 8.38%; p < 0.0001), while the endosteal diameter decreased (-4.64%, CI -7.15 to -2.05; p < 0.001). Total bone width did not change significantly (0.68%, CI -1.17 to 2.57%; not significant (NS)). A gender effect was seen on bone width (p < 0.0001), endosteal diameter (p < 0.01) and cortical thickness (p < 0.01), but not with MCI (NS). CONCLUSIONS: Cortical bone reacts promptly to reinstitution of GH beyond the attainment of final height by increasing the cortical thickness through endosteal bone growth. This leads to a higher peak bone mass and may reduce the risk of cortical bone fragility later in life.
Authors: Helene Holmer; Johan Svensson; Lars Rylander; Gudmundur Johannsson; Thord Rosén; Bengt-Ake Bengtsson; Marja Thorén; Charlotte Höybye; Marie Degerblad; Margareta Bramnert; Erik Hägg; Britt Edén Engström; Bertil Ekman; Karl-Göran Thorngren; Lars Hagmar; Eva-Marie Erfurth Journal: J Bone Miner Res Date: 2007-12 Impact factor: 6.741
Authors: G S Conway; M Szarras-Czapnik; K Racz; A Keller; P Chanson; M Tauber; M Zacharin Journal: Eur J Endocrinol Date: 2009-03-26 Impact factor: 6.664
Authors: Sandra R Torres; Curtis S K Chen; Brian G Leroux; Peggy P Lee; Lars G Hollender; Michelle Lloid; Shane Patrick Drew; Mark M Schubert Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2015-02-14
Authors: Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas Journal: Physiol Rev Date: 2017-01 Impact factor: 37.312
Authors: David Zeitoun; Guavri Caliaperoumal; Morad Bensidhoum; Jean Marc Constans; Fani Anagnostou; Valérie Bousson Journal: Eur Radiol Exp Date: 2019-04-11
Authors: Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni Journal: Front Endocrinol (Lausanne) Date: 2021-02-24 Impact factor: 5.555
Authors: Mirjana Doknic; Marko Stojanovic; Ivan Soldatovic; Tatjana Milenkovic; Vera Zdravkovic; Maja Jesic; Sladjana Todorovic; Katarina Mitrovic; Rade Vukovic; Dragana Miljic; Dragan Savic; Mihajlo Milicevic; Aleksandar Stanimirovic; Vojislav Bogosavljevic; Sandra Pekic; Emilija Manojlovic-Gacic; Aleksandar Djukic; Danica Grujicic; Milan Petakov Journal: Endocr Connect Date: 2021-08-13 Impact factor: 3.335